<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131377</url>
  </required_header>
  <id_info>
    <org_study_id>AMCAZM-150</org_study_id>
    <nct_id>NCT01131377</nct_id>
  </id_info>
  <brief_title>Acetazolamide Facilitates Ventilator Weaning</brief_title>
  <official_title>Acetazolamide Facilitates Ventilator Weaning Multicenter, Prospective, Double Blinded, Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic alkalosis(MA) is common metabolic disorder in ICU setting. MA could be cause of
      weaning failure or delay by depression of respiratory center. The purpose of this study is to
      evaluate that correction of MA by administration of acetazolamide facilitates weaning of
      mechanical ventilation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>weaning time between two group</measure>
    <time_frame>hour</time_frame>
    <description>Weaning time : [total ventilation time] - [total controlled mode time]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful weaning rate between two group</measure>
    <description>Successful weaning : self respiration more than 48h after withdrawl mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total duration of mechanical ventilation between two group</measure>
    <time_frame>hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of ICU stay between two group</measure>
    <time_frame>hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of ventilator associated pneumonia between two group</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall ICU mortality between two group</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Ventilator Weaning</condition>
  <condition>Alkalosis, Metabolic</condition>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If ABGA is pH ≥ 7.43 &amp; HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV.
If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will be managed with general metabolic alkalosis treatment such as electrolyte correction, hydration except acetazolamide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetazolamide</intervention_name>
    <description>If ABGA is pH ≥ 7.43 &amp; HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV q 24h.
If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip.</description>
    <arm_group_label>Acetazolamide</arm_group_label>
    <other_name>acetazolamide = Zoladin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>They will receive saline 50ml via IV q 24h.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients on mechanical ventilation for at least 24 hours with an assisted mode and
             passed acute resuscitation and considered for weaning. (Definition of Weaning point:

               1. Oxygenation

                    -  FiO2 ≤ 0.4 &amp; PaO2 ≥ 60 mmHg

                         -  O2 index (PaO2/FiO2) ≥ 150

                              -  SaO2 &gt; 90%

                                   -  PEEP ≤ 5 cmH2O

                                        -  MN ≤ 15 L/min

               2. Vital sign

                    -  Stable BP: MAP ≥ 60 mmHg ((i.e., no epinephrine or norepinephrine
                       &lt;0.2μg/kg/min, or equivalent dose vasopressin or phenylephrine)

                         -  HR ≤ 140bpm

                              -  35 ≤ BT ≤ 38 ℃

                                   -  RR ≤ 35/min

               3. Clinical status

                    -  resolution of acute disease process

                         -  no newly developed pulmonary infiltration

                              -  Ramsay sedation score 2~4

                                   -  Hb &gt; 7, pH &gt; 7.30, normal electrolyte

                                        -  no active bleeding, no IICP, no bronchospasm, no CAD

                                             -  no rescure or specific treatment (NO, prone, OP
                                                plan)

          -  ABGA : pH ≥ 7.43 and HCO3- ≥ 26mEq/L

        Exclusion Criteria:

          -  Permanent ventilator dependency due to brainstem disease, diffuse cerebral disease,
             severe respiratory or neuromuscular disease

          -  Active bleeding, IICP, unstable coronary artery disease, bronchospasm, and rescue
             treatment (inhaled NO, prone), pre-op condition

          -  Contraindication to acetazolamide: renal insufficiency (creatinine clearance &lt;20
             ml/min and/or renal replacement therapy), intolerance or allergy to acetazolamide or
             sulfonamides, hyperchloremic metabolic acidosis, hyponatremia (Na&lt;130), hypokalemia
             (K&lt;3.5), adrenal insufficiency.

          -  Diaphragm dysfunction : as diagnosed by fluoroscopy, nerve conduction velocity, USG,
             or overt paradoxical motion of the abdomen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chae-Man Lim, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eun Young Choi, Fellow</last_name>
    <phone>+82-2-3010-3894</phone>
    <email>letact@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chae-Man Lim, professor</last_name>
    <phone>+82-2-3010-3135</phone>
    <email>cmlim@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AMC MICU; Asan medical center</name>
      <address>
        <city>Seoul</city>
        <state>388-1, Pungnap-dong, Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chae-Man Lim, professor</last_name>
      <phone>+82-2-3010-3135</phone>
      <email>cmlim@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Eun Young Choi, fellow</last_name>
      <phone>+82-2-3010-3894</phone>
      <email>letact@hanmail.net</email>
    </contact_backup>
    <investigator>
      <last_name>Eun Young Choi, fellow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>May 26, 2010</last_update_submitted>
  <last_update_submitted_qc>May 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chae-Man Lim/Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea</name_title>
    <organization>Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea</organization>
  </responsible_party>
  <keyword>mechanical ventilation weaning phase patients with metabolic alkalosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alkalosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

